Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2004

View Archived Issues

Expansion of Seattle Genetics/Genentech ADC collaboration

Pharmacopeia delivers development candidate in Organon collaboration

Ono and Merck & Co. in licensing agreements

Genentech and Rinat Neuroscience to codevelop and commercialize RI-624

Neurocrine Biosciences enters Parkinson's licensing agreement with Almirall

Peregrine and NABTT collaborate on Cotara study

Disappointing preliminary results of Trabio study

Orphan drug status for intravenous terlipressin for type 1 hepatorenal syndrome

New treatment for Alzheimer's disease claimed by Ares

Formulations for nasal delivery of loratadine described by Ranbaxy

Ranbaxy claims new lamotrigine formulations for epilepsy

A series of cytidine nucleoside analogues described in patent literature

Protein kinase modulators claimed by Sugen

Two series of CFR1 receptor antagonists disclosed

Cell Therapeutics researchers claim anticancer compounds

PYM-50018 awarded fast track status for ALS

Dusa and NCI to evaluate Levulan for oral cavity dysplasia

Novartis selects Vertex collaboration drug candidate for clinical development

Immtech completes African sleeping sickness study of DB-289

New data on the pharmacokinetics and antifungal effects of BAL-4815 and BAL-8557

Final phase II data on the antiviral efficacy of ANA-380 in HBV infection

A phase I/II trial confirms the efficacy and safety of NM-283 in hepatitis C

Valtorcitabine reported safe and effective in chronic hepatitis B

Novel DpT analogues show potent and selective antitumor activity

Cardioprotective effects of IAA-94 against doxorubicin-induced contractile dysfunction and apoptosis

Perlecan-inducing stent coating reduces intimal hyperplasia

Novel anticoccidial agent from Romark

Dual targeting of gyrase and topisomerase IV effective against Gram-positive and -negative pathogens

DNA polymerase III holoenzyme inhibitors with potent bactericidal activity

Novel polymerase target for HCV therapy

Merck selects integrin alphavbeta3 antagonist for development for osteoporosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...